▶주메뉴 바로가기
▶본문 바로가기
LG Chem, South Korea’s top chemical firm, said on March 11 it has received a $33.4 million grant from the Bill & Melinda Gates Foundation to develop a new combination vaccine. The grant will be used to develop the 6-in-1 vaccine for simultaneous protection against six serious diseases -- dipht...
Celltrion Healthcare announced on March 11 that it won bids to supply Remsima and Truxima to two Southeast Asian countries at the end of last year. For this year, the company will be exclusively supplying Remsima, its biosimilar of Johnson & Johnson’s autoimmune disease therapy Remicade, to Singa...
Stonebridge Ventures, spun-off from Korean private equity firm Stonebridge Capital, will invest more in the bio industry this year, according to industry sources on March 8. “Recently, we saw growing demand for funding in the bio industry, so we decided to hire more employees with related experti...
Korean biopharmaceutical firm Samsung Bioepis will spend 180.4 billion won (US$159.70) to build a new research and development center, its parent company said Thursday. The investment cost accounts for 36.44 percent of the company’s capital at the end of 2017, Samsung BioLogics, a biopharmaceu...
Daewoong Pharmaceutical announced on March 6 that it posted sales of 1.31 trillion won (US$ 1.16 billion) last year. It has became one of the few Korean pharma firms to reach the milestone. Three other local companies -- Kolmar Korea, GC Pharma and Hanmi Pharmaceutical -- crossed the landmark figu...
SillaJen aims to secure around 220 billion won (US$194.89 million) fresh funds through issuing convertible bonds, according to industry sources on March 7. It has picked Kium Securities to organize the deal with investors. According to sources, the official decision to secure new funds will be co...
Stock exchange operator Korea Exchange has blocked condom maker Bio Genetics from getting representation on Kyung Nam Pharm’s board, according to industry sources on Mar. 6. Bio Genetics, which bought an 11.29 percent stake in Kyung Nam Pharm, had aimed to get representation through an extraordin...
Korean biopharmaceutical firm Samsung Bioepis said on March 5 it has won approval from European authorities for the sale of mass dosages of its biosimilar drug Ontruzant. The European Medicines Agency accepted Samsung Bioepis’ application to sell the 420 mg biosimilar product referencing Switz...
Hypertension drugs gained unwanted attention in South Korea last year: More than 170 generic drugs sold by 76 local drugmakers were recalled by the Drug Ministry for their inclusion of valsartan, a chemical substance that could raise the risk of cancer. However, the industry is looking for a rebou...
Ildong Pharmaceutical’s multivitamin series Aronamin was the best-selling over the counter drug for the third consecutive year in 2018. OTC drugs can be purchased directly at medical stores without a doctor’s prescription. According to health care consulting firm IQVIA on Mar. 3, Aronamin marke...
Korean cosmetics manufacturer Kolmar Korea has decided to issue corporate bonds worth 100 billion won (US$89.35 million), according to industry sources on Feb. 28. Mirae Asset Daewoo is organizing its funding. According to sources, the firm initially planned to issue bonds worth 70 billion won an...
Celltrion Pharm, the generic arm of Celltrion, announced on Feb. 27 that it has decided to inject 58.2 billion won for establishing its Remsima SC production facility at its plant in Cheongju, North Chungcheong Province. Remsima SC is a subcutaneous version of Remsima, its biosimilar of Johnson & ...
SK Biopharmaceuticals, the new drug development unit of Korea’s telecom-to-energy conglomerate SK Group, is considering exporting its drug candidate Cenobamate to Japan, according to industry sources on Feb. 26. Cenobamate was developed as an epilepsy treatment. The company is now conducting phas...
Hong Kong-based global private equity firm Anchor Equity Partners plans to sell its 47 percent stake in Korean top drug retailer Geoyoung, according to industry sources on Feb. 25. The PEF has reportedly picked Citigroup Global Markets Korea Securities as it manager to organize the sale of Geoyoun...
Kyung Nam Pharm, a local drug maker known for its vitamin supplement product Lemona, is once again looking for an owner after failing to sign a deal with South Korean media company KMH Group in 2018. So far, two local companies -- Bio Genetics and Next BT-- have expressed a willingness to make the...
[KH Explains] Why foreign investors continue to be net buyers despite short selling ban
Incheon Airport traffic nears pre-pandemic levels
[Hello Indonesia] Korea, Indonesia’s exchanges highlighted at talk session
EcoPro, Samsung SDI clinch W44tr cathode supply deal
Short selling ban important for Korean market development: FSC
LG Energy Solution CEO emphasizes qualitative growth
KAI, SpaceX to launch Korea's next-gen satelllites in 2025
SK chief suggests Korean, Japanese businesses form ‘union’ to overcome global crisis